Long-term Treatment of Acromegaly with Lanreotide：Evidence of Increased Serum Parathormone Concentration

The somatostatin analogue lanreotide is effective in reducing growth hormone levels in patients with acromegaly. Acromegaly is characterized by calcium homeostasis alterations. The aim of our study was to evaluate the effects of lanreotide on bone turnover markers in a group of acromegalic patients...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL 2004, Vol.51 (6), p.517-520
Main Authors: CARLO CAPPELLI, ELENA GANDOSSI, BARBARA AGOSTI, BRUNO CERUDELLI, DAVIDE CUMETTI, MAURIZIO CASTELLANO, ILENIA PIROLA, ELVIRA DE MARTINO, ENRICO AGABITI ROSEI
Format: Article
Language:Japanese
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The somatostatin analogue lanreotide is effective in reducing growth hormone levels in patients with acromegaly. Acromegaly is characterized by calcium homeostasis alterations. The aim of our study was to evaluate the effects of lanreotide on bone turnover markers in a group of acromegalic patients and to verify a possible increase of intact parathormone (iPTH) levels in a transient or persistent way. Serum GH, IGF-I and serum and urinary markers of bone metabolism were measured before treatment and on months 3 and 24. In short-term treatment (3 months), lanreotide significantly decreased GH, IGF-I, serum calcium, osteocalcin and alkaline phosphatase levels, but increased iPTH level (49±16.7 vs pre-treatment 28.3±7.6 ng/L, p
ISSN:0918-8959